244 related articles for article (PubMed ID: 36776374)
1. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma.
Wen J; Zhao W; Shu X
Front Oncol; 2022; 12():1087762. PubMed ID: 36776374
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
3. Machine Learning-Based Integration Develops a Pyroptosis-Related lncRNA Model to Enhance the Predicted Value of Low-Grade Glioma Patients.
Wu J; Lu L; Wang C; Jiang F
J Oncol; 2022; 2022():8164756. PubMed ID: 35646114
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
Front Oncol; 2022; 12():988680. PubMed ID: 36203428
[TBL] [Abstract][Full Text] [Related]
5. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
Front Oncol; 2022; 12():966920. PubMed ID: 36276132
[TBL] [Abstract][Full Text] [Related]
6. Novel Cuproptosis-Related Gene Signature for Precise Identification of High-Risk Populations in Low-Grade Gliomas.
Chen P; Han H; Wang X; Wang B; Wang Z
Mediators Inflamm; 2023; 2023():6232620. PubMed ID: 36814682
[TBL] [Abstract][Full Text] [Related]
7. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
Wang X; Jing H; Li H
Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
[TBL] [Abstract][Full Text] [Related]
8. Foreboding lncRNA markers of low-grade gliomas dependent on metabolism.
Lu Z; Feng Y
Medicine (Baltimore); 2022 Nov; 101(44):e31302. PubMed ID: 36343057
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
11. Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma.
Miao Y; Liu J; Liu X; Yuan Q; Li H; Zhang Y; Zhan Y; Feng X
Front Genet; 2022; 13():951239. PubMed ID: 36186436
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
13. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
14. Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma.
Shi Y; Sheng P; Guo M; Chen K; Zhou H; Wu M; Li W; Li B
Front Genet; 2023; 14():1100909. PubMed ID: 37470034
[No Abstract] [Full Text] [Related]
15. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and immune response of a cuproptosis-related lncRNA signature in low grade glioma.
Xu Y; Wang C; Li S; Zhou H; Feng Y
Front Genet; 2022; 13():975419. PubMed ID: 36338998
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
18. A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma.
Yan X; Wang N; Dong J; Wang F; Zhang J; Hu X; Zhao H; Gao X; Liu Z; Li Y; Hu S
Front Mol Biosci; 2022; 9():966843. PubMed ID: 36060266
[TBL] [Abstract][Full Text] [Related]
19. Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma.
Qiao Q; Wang Y; Zhang R; Pang Q
Transl Cancer Res; 2022 Jul; 11(7):2157-2174. PubMed ID: 35966301
[TBL] [Abstract][Full Text] [Related]
20. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]